Quantum Genomics Valuation
| ALQGC Stock | EUR 0.07 0 1.77% |
Quantum Genomics seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Quantum Genomics from analyzing the company fundamentals such as Current Valuation of (11.33 M), shares owned by insiders of 9.18 %, and Return On Equity of -1.23 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Quantum Genomics' price fluctuation is very steady at this time. Calculation of the real value of Quantum Genomics is based on 3 months time horizon. Increasing Quantum Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Quantum Genomics' intrinsic value may or may not be the same as its current market price of 0.07, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0721 | Real 0.0606 | Hype 0.0721 | Naive 0.0721 |
The intrinsic value of Quantum Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Quantum Genomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Quantum Genomics SA helps investors to forecast how Quantum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Quantum Genomics more accurately as focusing exclusively on Quantum Genomics' fundamentals will not take into account other important factors: Quantum Genomics Total Value Analysis
Quantum Genomics SA is presently projected to have takeover price of (11.33 M) with market capitalization of 5.65 M, debt of 283.69 K, and cash on hands of 5.01 M. The negative valuation of Quantum Genomics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Quantum Genomics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(11.33 M) | 5.65 M | 283.69 K | 5.01 M |
Quantum Genomics Investor Information
The company has price-to-book (P/B) ratio of 0.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. Quantum Genomics recorded a loss per share of 0.73. The entity had not issued any dividends in recent years. The firm had 1:18 split on the 13th of December 2013. Based on the key indicators related to Quantum Genomics' liquidity, profitability, solvency, and operating efficiency, Quantum Genomics SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Quantum Genomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Quantum Genomics has an asset utilization ratio of 0.51 percent. This connotes that the Company is making €0.005145 for each dollar of assets. An increasing asset utilization means that Quantum Genomics SA is more efficient with each dollar of assets it utilizes for everyday operations.Quantum Genomics Ownership Allocation
Quantum Genomics owns a total of 34.53 Million outstanding shares. Quantum Genomics holds 9.18 pct. of its outstanding shares held by insiders and 3.69 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Quantum Genomics Profitability Analysis
The company reported the revenue of 116.21 K. Net Loss for the year was (17.36 M) with loss before overhead, payroll, taxes, and interest of (12.47 M).About Quantum Genomics Valuation
The stock valuation mechanism determines Quantum Genomics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Quantum Genomics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Quantum Genomics. We calculate exposure to Quantum Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Quantum Genomics's related companies.Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people.
8 Steps to conduct Quantum Genomics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Quantum Genomics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Quantum Genomics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Quantum Genomics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Quantum Genomics' revenue streams: Identify Quantum Genomics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Quantum Genomics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Quantum Genomics' growth potential: Evaluate Quantum Genomics' management, business model, and growth potential.
- Determine Quantum Genomics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Quantum Genomics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.